Glycemic Outcomes During Real-World Hybrid Closed-Loop System Use by Individuals With Type 1 Diabetes in the United States

17Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Glycemic outcomes during real-world hybrid closed-loop (HCL) system use by individuals with type 1 diabetes, in the United States, were retrospectively analyzed. Methods: Hybrid closed-loop system data voluntarily uploaded to Carelink™ personal software from March 2017 to November 2020 by individuals (aged ≥7 years) using the MiniMed™ 670G system and having ≥10 days of continuous glucose monitoring data after initiating Auto Mode were assessed. Glycemic outcomes including the mean glucose management indicator (GMI), sensor glucose (SG), percentage of time spent in (TIR), below (TBR), and above (TAR) target range (70-180 mg/dL) were analyzed. Outcomes were also analyzed in a subgroup of users per baseline GMI of <7% versus >8%. Results: The overall cohort (N = 123 355 users, with a mean of 87.9% of time in Auto Mode) had a GMI of 7.0% ± 0.4%, TIR of 70.4% ± 11.2%, TBR <70 mg/dL of 2.2% ± 2.1% and TAR>180 mg/dL of 27.5% ± 11.6%, post-Auto Mode initiation. Compared with pre-Auto Mode initiation, users (N = 52 941, 88.6% of time in Auto Mode) had a GMI that decreased from 7.3% ± 0.6% to 7.1% ± 0.5% (P 180 mg/dL that decreased from 36.3% ± 15.7% to 29.8% ± 12.2% (P <70 mg/dL that decreased from 2.11 ± 2.4 to 2.07% ± 2.25% (P =.002). While all metrics statistically improved for the baseline GMI >8.0% group, the baseline GMI <7.0% group had unchanged TIR (77.4% ± 7.4% to 77.5% ± 8.0%, P =.456) and TAR>180 mg/dL that increased (19.2 ± 6.7 to 19.6 ± 7.9%, p < 0.001). Conclusion: Real-world HCL system use in the U.S. demonstrated overall glycemic control that trended similarly with the system pivotal trial outcomes and previous real-world system use analyses.

References Powered by Scopus

Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range

2475Citations
N/AReaders
Get full text

State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018

1396Citations
N/AReaders
Get full text

Glycemic targets: Standards of medical care in diabetes−2021

0
665Citations
N/AReaders
Get full text

Cited by Powered by Scopus

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024

0
222Citations
N/AReaders
Get full text

Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial

25Citations
N/AReaders
Get full text

Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor

14Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Arunachalum, S., Velado, K., Vigersky, R. A., & Cordero, T. L. (2023). Glycemic Outcomes During Real-World Hybrid Closed-Loop System Use by Individuals With Type 1 Diabetes in the United States. Journal of Diabetes Science and Technology, 17(4), 951–958. https://doi.org/10.1177/19322968221088608

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

100%

Readers' Discipline

Tooltip

Medicine and Dentistry 2

67%

Chemistry 1

33%

Save time finding and organizing research with Mendeley

Sign up for free